India, Nov. 2 -- Krystal Biotech Inc. (KRYS), a commercial-stage biotechnology company, on Monday released financial results for the third quarter, recording a lower profit as high revenues were offset by increased income tax expenses.
The company focuses on the discovery, development, and commercialization of genetic medicines for rare diseases. Products marketed by Krystal include VYJUVEK, a redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).
Q3 Financial Results:
Net income for the three months ending September 30, 2026, amounted to $63.07 million or $2.05 per share, compared to $79.36 million or $2.66 per share in the same period of 2025.
The mild decrease may be attributed to an income tax expense of...